Authors: Lowe, ES Kitchen, BJ Erdmann, G Stork, LC Bostrom, BC Hutchinson, R Holcenberg, J Reaman, GH Woods, W Franklin, J Widemann, BC Balis, FM Murphy, RF Adamson, PC

Citation: Es. Lowe et al., Plasma pharmacokinetics and cerebrospinal fluid penetration of thioguaninein children with acute lymphoblastic leukemia: a collaborative pediatric oncology branch, NCI, and Children's Cancer Group study, CANC CHEMOT, 47(3), 2001, pp. 199-205

Authors: Goodkin, DE Shulman, M Winkelhake, MJ Waubant, E Andersson, PB Stewart, T Nelson, S Fischbein, N Coyle, PK Frohman, E Jacobs, L Holcenberg, J Lee, M Mocci, S

Citation: De. Goodkin et al., A phase I trial of solubilized DR2 : MBp(84-102) (AG284) in multiple sclerosis, NEUROLOGY, 54(7), 2000, pp. 1414-1420

Authors: Goodkin, DE Andersson, PB Waubant, E Stewart, T Garia, A Chan, A Goldstein, R Nelson, S Coyle, P Frohman, E Jacobs, L Lee, M Winkelhake, J Holcenberg, J Shulman, M

Citation: De. Goodkin et al., A double blind, dose escalation study of safety and tolerability of IV AG284 in patients with SP multiple sclerosis, MULT SCLER, 4(6), 1998, pp. 508-508